1. Baggott, M. J., Erowid, E., Erowid, F., & Mendelson, J. E. (2004). Use of salvia divinorum, an unscheduled hallucinogenic plant: A web-based survey of 500 users. Clinical Pharmacology and Therapeutics 75, 72.
2. Chavkin, C., Sud, S., Jin, W., Stewart, J., Zjawiony, J. K., Siebert, D. J., et al. (2004). Salvinorin A, an active component of the hallucinogenic sage Salvia divinorum, is a highly efficacious kappa opioid receptor agonist: Structural and functional considerations. The Journal of Pharmacology and Experimental Therapeutics, 308(3), 1197–1203.
3. Devine, D. P., Leone, P., Pocock, D., & Wise, R. A. (1993). Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: in vivo microdialysis studies. The Journal of Pharmacology and Experimental Therapeutics, 266, 1236–1246.
4. Di Chiara, G., & Imperato, A. (1988). Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. The Proceedings of the National Academy of Sciences of the USA, 85, 5274–5278.
5. Donzanti, B. A., Althaus, J. S., Payson, M. M., & Von Voigtlander, P. F. (1992). Kappa agonist-induced reduction in dopamine release: Site of action and tolerance. Research Communications in Chemical Pathology and Pharmacology, 78, 193–210.